A life sciences venture firm that grew out of Frazier Healthcare Partners in Seattle and now operates independently, backing private and public biotech companies.
Frazier Life Sciences Management, L.P. is described on the Frazier Healthcare Partners website as a 'separate and independent legal' entity from Frazier Management, LLC, with 'any prior affiliation between the firms' now 'fully terminated'. Frazier Healthcare Partners itself was founded in 1991 by Alan Frazier in Seattle (Wikipedia). The life sciences arm historically invested in company creation and later-stage private and public biotechs from offices in Seattle and the San Francisco Bay Area. At the time of research the frazierlifesciences.com domain returned only a blank page redirecting to a parking address, so the firm's own description, current offices and oncology portfolio could not be confirmed from a fetched primary source.
| Company | Stage | Type | Cancers | Latest round |
|---|---|---|---|---|
| Alentis Therapeutics Basel, CH | Growth stage | biotech | Series D 2024, $181M | |
| Alpha-9 Oncology Vancouver, CA | Growth stage | radiopharma | Melanoma | Series C 2024, $175M |
| Callio Therapeutics Seattle, WA, US | Startup | biotech | HER2-positive breast cancer | Series A 2025, $187M |
| Enlaza Therapeutics La Jolla, CA, US | Startup | biotech | Series A 2024, $100M | |
| Enliven Therapeutics Boulder, CO, US | Public | biotech | Non-small-cell lung cancer | Crossover 2023, $165M |
| Radionetics Oncology San Diego, CA, US | Startup | radiopharma | Series A 2024, $53M |
Shares Radionetics Oncology, Enliven Therapeutics and the tag vc.
Shares Enlaza Therapeutics, Alpha-9 Oncology and the tag vc.
Shares Enlaza Therapeutics, Alpha-9 Oncology and the tag vc.
Shares Alentis Therapeutics, Callio Therapeutics and the tag vc.
Shares Alentis Therapeutics, Callio Therapeutics and the tag vc.
Shares Enliven Therapeutics, Alentis Therapeutics, Alpha-9 Oncology and the tag vc.
Shares Radionetics Oncology and the tag vc.
Shares Alpha-9 Oncology and the tag vc.